Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Poolbeg Pharma Ltd. ( (GB:POLB) ) has shared an announcement.
Poolbeg Pharma plc and HOOKIPA Pharma Inc. are engaged in non-binding discussions for a possible all-share acquisition by HOOKIPA. This potential merger aims to create a robust biopharmaceutical entity with a focus on immunotherapies for cancer and other serious diseases. The discussions have been positive, and due diligence is ongoing, prompting an extension of the deadline for HOOKIPA to decide on a formal offer. Gilead Sciences Inc. has shown its intention to support the proposal and participate in a concurrent fundraise, potentially enhancing the financial backing for the deal.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma Ltd. is a clinical-stage biopharmaceutical company focusing on the development and commercialization of innovative medicines targeting critical unmet medical needs. The company specializes in next-generation immunotherapies for the treatment of cancer and other serious diseases.
YTD Price Performance: -26.76%
Average Trading Volume: 2,156,749
Technical Sentiment Consensus Rating: Buy
Learn more about POLB stock on TipRanks’ Stock Analysis page.
